Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

* Histologically or cytologically confirmed solid tumors that fulfill ≥ 1 of the following criteria:

  * BRCA1/2 mutation and a BRCA-related malignancy

    * Patients without a known BRCA mutation must have a probability of harboring a BRCA gene mutation as assessed by BRCAPRO computer program
    * Patients with a probability of having genetic mutation ≥ 20% or a BRCA mutation based on a non-Myriad test, must have a formal BRCA testing by Myriad Genetic Laboratories
    * Patients with known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
    * Patients who refuse BRCA testing not allowed unless they have another acceptable histology
  * First- or second-line metastatic colorectal cancer
  * Any-line metastatic mucinous ovarian cancer
  * Any line of other metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity (i.e., gastric or pancreatic adenocarcinoma)
* Patients with uncontrolled CNS metastasis are not eligible; patients with CNS metastases who have had them treated and are stable for \> 3 months will be eligible; patients must be off steroid treatment prior to study enrollment
* Measurable disease

  * Patients with ovarian cancer who have a pre-treatment CA 125 level of at least twice the upper limit of normal allowed
* ECOG performance status (PS) 0-2 (Karnofsky 60-100%)
* Life expectancy \> 3 months
* ANC ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)
* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
* Fertile patients must use adequate contraception (i.e., hormonal, barrier method of birth control, or abstinence)
* Not pregnant or nursing
* Negative pregnancy test
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
* No uncontrolled intercurrent illness including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric illness and/or social situations that would limit compliance with study requirements
* No history of positive serology for hepatitis A, B, or C, liver disease, or other forms of hepatitis or cirrhosis
* Patients who have active seizures or history of seizures are ineligible
* No condition that impairs the ability to swallow and retain veliparib capsules, including any of the following:

  * Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
  * Prior surgical procedures affecting absorption
  * Active peptic ulcer disease
* No malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction
* No peripheral neuropathy ≥ grade 2
* No prolonged QTC \> 450 msec (male) or QTC \> 470 (female)
* No concurrent combination antiretroviral therapy for HIV-positive patients
* Recovered from adverse events of prior therapy or prior surgical procedures

  * Patients with chronic grade 1 or 2 adverse events that are not expected to improve are allowed at investigator's discretion
* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
* At least 4 weeks since prior radiotherapy with no \> 35% of marrow irradiation
* Prior fluoropyrimidine allowed
* Prior veliparib allowed provided it was part of a single- or limited-dosing study, such as a phase 0 study
* Prior capecitabine allowed provided patient tolerated 3500 mg/m² for 7 days out of 14 days
* No other prior investigational agents
* No prior oxaliplatin